Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 18/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 4/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6433400 | 0.82 | CA12 (0.36) | CNR2CNR1CA12CA1CA9 | |
| SCHEMBL6433716 | 0.82 | CA12 (0.36) | CNR2CNR1CA12CA1CA9 | |
| SCHEMBL6433023 | 0.82 | CA12 (0.36) | CNR2CNR1CA12CA1CA9 | |
| SCHEMBL6434340 | 0.81 | CA12 (0.39) | CA12CA1CA9 | |
| SCHEMBL6433948 | 0.78 | CA12 (0.39) | CNR2DRD2CA12CA1CA9 | |
| SCHEMBL6499011 | 0.78 | CA12 (0.39) | CNR2DRD2CA12CA1CA9 | |
| SCHEMBL6433944 | 0.78 | CA12 (0.39) | CNR2DRD2CA12CA1CA9 | |
| SCHEMBL6434515 | 0.78 | CA12 (0.39) | CNR2DRD2CA12CA1CA9 | |
| SCHEMBL6433895 | 0.77 | CA12 (0.36) | CNR2CNR1CA12CA1CA9 | |
| SCHEMBL6440743 | 0.77 | DRD2 (0.39) | DRD2CA12CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6933319-B2 | Resorcinol derivatives | PFIZER INC. (US) | 2005-08-23 | — | — | US | disclosed |
| US-6828460-B2 | Containing at least one ester, oxime, sulfonamide, hydroxyamino or alkyoxyamino functionality; skin lightening agents; tyrosinase inhibitors | PFIZER INC. | 2004-12-07 | — | — | US | disclosed |
| US-20040209949-A1 | Resorcinol derivatives | BROWNING ANDREW FRANCIS (SE) | 2004-10-21 | — | — | US | disclosed |
| US-20020161041-A1 | Resorcinol derivatives | PFIZER INC. | 2002-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209949-A1 | Resorcinol derivatives | NQO1, LRAT, ALDH1A2 | CNR2 4083/4885DRD2 398/4885CNR1 3969/4885 |
| US-20020161041-A1 | Resorcinol derivatives | NQO1, LRAT, ALDH1A2 | CNR2 4083/4885DRD2 398/4885CNR1 3969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.